PAYS - Paysign, Inc.
Paysign NASDAQ: PAYS operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation.
Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Paysign, Inc. (PAYS) and Sezzle Inc. (SEZL) have performed compared to their sector so far this year.
Dimensional Fund Advisors LP increased its stake in shares of Paysign, Inc. (NASDAQ: PAYS) by 16.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 575,619 shares of the company's stock after purchasing an additional 82,736 shares during
Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Paysign NASDAQ: PAYS reported record second-quarter revenue, net income and adjusted EBITDA for 2026, driven primarily by continued expansion in its Patient Affordability business and improving utilization in its plasma donor compensation operations.
Paysign, Inc. (PAYS) Q2 2026 Earnings Call Transcript
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive pharma patient affordability offerings, financial technology products and integrated payment processing, today announced financial results for the second quarter 2026. “Paysign delivered a strong second quarter, achieving record revenue, net income, and adjusted EBITDA while continuing to expand margins,” said Mark Newcomer, President and CEO of Paysign. “Strong growth in o.
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, will discuss second quarter 2026 earnings at 5:00 p.m. Eastern time on Wednesday, August 5, 2026. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.68.
Paysign, Inc. (NASDAQ: [url="]PAYS[/url]), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platfo
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026.
Paysign, Inc. (NASDAQ: [url="]PAYS[/url]), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platfo
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference.
Paysign handily beat Wall Street analysts in the first quarter but didn't raise guidance. The stock looks cheap.
Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript
Wix.com revenue growth continues, PaySign beats Q1 management guidance, and more
Paysign NASDAQ: PAYS reported what executives described as the strongest start to a year in the company's history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and profitability expanding sharply as its patient affordability business became its largest revenue contributor.
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026.
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host First Quarter 2026 Earnings Call.